Predicting the future burden of NAFLD and NASH
While the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) continues to rise, with both conditions increasingly recognised in primary care and specialist practice, quantifying future disease burden has always been challenging. This is largely due to the diagnostic tools currently available for NAFLD diagnosis. Ultrasound is poorly sensitive for milder forms of hepatic steatosis, while liver enzymes are variably elevated in NAFLD and may be normal in 50–80% of cases.
To read the full article, visit: Journal of Hepatology